Loading clinical trials...
Loading clinical trials...
A Phase I Study to Investigate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics(PK) of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Conditions
Interventions
SCR-6920 capsule
SCR-6920 capsule
+2 more
Locations
1
China
Shandong Cancer Hospital
Jinan, Shandong, China
Start Date
May 18, 2022
Primary Completion Date
October 1, 2027
Completion Date
October 1, 2027
Last Updated
September 6, 2022
NCT05529069
NCT06898450
NCT05720117
NCT06658951
NCT06625775
NCT05098132
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions